Summary

The Middle East and Africa calcineurin inhibitors market is expected to reach USD 642.19 million by 2032 from USD 320.58 million in 2024, growing with a CAGR of 9.1% in the forecast period of 2024 to 2032.

Market Segmentation:
Middle East and Africa Calcineurin Inhibitors Market, By Drugs (Tacrolimus, Cyclosporine, Pimecrolimus, Voclosporin, and Others), Route of Administeration (Oral, Topical, Parenteral, and Others), Drug type (Branded and Generic), Application (Postoperative Immunosuppression, Atopic Dermatitis, Ulcerative Colitis, Psoriasis, Keratoconjunctivitis, and Others), End user (Hospitals, Specialty Clinics, Home Healthcare, Academic and Research Institutes, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others), Country (South Africa, Saudi Arabia, U.A.E., Egypt, Kuwait, Israel, and Rest Of Middle East And Africa) - Industry Trends And Forecast To 2032

Overview of Middle East and Africa Calcineurin Inhibitors Market Dynamics:

Driver
• Rising Prevalence Of Autoimmune Diseases
Restraint

• Limited Efficacy For Long-Term Use Of Calcineurin Inhibitors
Opportunity

• Growing Demand For Personalized Medicine

Market Players:

The key market players operating in the Middle East and Africa calcineurin inhibitors market are listed below:

• Astellas Pharma US, Inc. (U.S),
• Lupin (India)
• Viatris Inc. (U.S.)
• Glenmark Pharmaceuticals Inc. (India)
• Bausch Health Companies Inc. (Canada)
• AbbVie Inc. (U.S.)
• SANDOZ (Switzerland)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Dr. Reddy’s Laboratories Ltd. (India)
• Biocon (India)
• Apotex Inc. (Canada)
• Sun Pharmaceutical Industries Ltd. (India)

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1 INTRODUCTION 24
1.1 OBJECTIVES OF THE STUDY 24
1.2 MARKET DEFINITION 24
1.3 OVERVIEW OF THE MIDDLE EAST AND AFRICA CALCINEURIN INHIBITORS MARKET 24
1.4 CURRENCY AND PRICING 26
1.5 LIMITATIONS 26
1.6 MARKETS COVERED 26
2 MARKET SEGMENTATION 30
2.1 MARKETS COVERED 30
2.2 GEOGRAPHICAL SCOPE 31
2.3 YEARS CONSIDERED FOR THE STUDY 32
2.4 DBMR TRIPOD DATA VALIDATION MODEL 33
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 36
2.6 MULTIVARIATE MODELLING 37
2.7 DBMR MARKET POSITION GRID 38
2.8 VENDOR SHARE ANALYSIS 39
2.9 SECONDARY SOURCES 40
2.10 ASSUMPTIONS 40
3 EXECUTIVE SUMMARY 41
4 PREMIUM INSIGHTS 46
4.1 PORTER’S FIVE FORCES 47
4.2 PESTEL ANALYSIS 48
5 APAC DEPRESSION SCREENING MARKET: REGULATIONS 49
5.1 REGULATORY AUTHORITIES IN NORTH AMERICA. 49
5.1.1 U.S. FOOD AND DRUG ADMINISTRATION (FDA) 49
5.1.2 HEALTH CANADA 50
5.1.3 FEDERAL COMMISSION FOR THE PROTECTION AGAINST SANITARY RISKS (COFEPRIS) - MEXICO 50
5.2 REGULATORY AUTHORITIES IN EUROPE. 51
5.2.1 GERMANY: 51
5.2.2 UNITED KINGDOM: 51
5.2.3 FRANCE: 51
5.2.4 ITALY: 51
5.2.5 SPAIN: 51
5.3 REGULATORY AUTHORITIES IN ASIA-PACIFIC. 52
5.3.1 JAPAN: 52
5.3.2 CHINA: 52
5.3.3 INDIA: 52
5.3.4 SOUTH KOREA: 52
5.3.5 AUSTRALIA: 53
5.4 REGULATORY AUTHORITIES IN MIDDLE EAST AND AFRICA. 53
5.4.1 SAUDI ARABIA: 53
5.4.2 UNITED ARAB EMIRATES (UAE): 53
5.4.3 EGYPT: 53
5.4.4 SOUTH AFRICA: 53
5.5 REGULATORY AUTHORITIES IN SOUTH AMERICA. 54
5.5.1 BRAZIL: 54
5.5.2 ARGENTINA: 54
5.5.3 COLOMBIA: 54
5.5.4 CHILE: 54
6 MARKET OVERVIEW 56
6.1 DRIVERS 58
6.1.1 RISING PREVALENCE OF AUTOIMMUNE DISEASES 58
6.1.2 INCREASING TRANSPLANTATION PROCEDURES 58
6.1.3 ADVANCEMENTS IN MEDICAL TECHNOLOGY 59
6.1.4 GOVERNMENT SUPPORT & FUNDING FOR TRANSPLANTS 60
6.2 RESTRAINTS 61
6.2.1 LIMITED EFFICACY FOR LONG-TERM USE OF CALCINEURIN INHIBITORS. 61
6.2.2 AVAILABILITY OF ALTERNATIVE IMMUNOSUPPRESSIVE THERAPIES. 61
6.3 OPPORTUNITIES 62
6.3.1 GROWING DEMAND FOR PERSONALIZED MEDICINE 62
6.3.2 GROWING GERIATRIC POPULATION 63
6.3.3 ADVANCEMENTS IN DRUG DELIVERY 63
6.4 CHALLENGES 64
6.4.1 COMPLEX DOSING AND MONITORING 64
6.4.2 HIGH COSTS 64
7 MIDDLE EAST AND AFRICA CALCINEURIN INHIBITORS MARKET, BY DRUGS 65
7.1 OVERVIEW 66
7.2 TACROLIMUS 69
7.2.1 GENERIC 69
7.2.2 BRANDED 70
7.2.2.1 PROGRAF 70
7.2.2.2 ASTAGRAF XL 70
7.2.2.3 ENVARSUS XR 70
7.2.2.4 OTHER 70
7.2.2.4.1 CAPSULES 70
7.2.2.4.2 TABLETS 70
7.2.2.4.3 INJECTIONS 71
7.2.2.4.4 GRANULES FOR ORAL SUSPENSION 71
7.2.2.4.4.1 1 MG 71
7.2.2.4.4.2 0.5 MG 71
7.2.2.4.4.3 5 MG 71
7.2.2.4.4.4 OTHERS 71
7.2.2.4.4.5 ADULT 72
7.2.2.4.4.6 GERIATRIC 72
7.2.2.4.4.7 PEDIATRIC 72
7.3 CYCLOSPORINE 72
7.3.1 GENERIC 72
7.3.2 BRANDED 73
7.3.2.1 NEORAL 73
7.3.2.2 SANDIMMUNE 73
7.3.2.3 GENGRAF 73
7.3.2.4 OTHERS 73
7.3.2.4.1 CAPSULES 74
7.3.2.4.2 ORAL SOLUTION 74
7.3.2.4.3 INJECTION 74
7.3.2.4.4 OTHERS 74
7.3.2.4.4.1 100 MG 74
7.3.2.4.4.2 25 MG 74
7.3.2.4.4.3 50 MG 74
7.3.2.4.4.4 OTHERS 74
7.3.2.4.4.5 ADULT 75
7.3.2.4.4.6 PEDIATRIC 75
7.3.2.4.4.7 GERIATRIC 75
7.4 PIMECROLIMUS (TOPICAL CREAM) 75
7.4.1 GENERIC 75
7.4.2 BRANDED 75
7.4.2.1 ADULT 76
7.4.2.2 GERIATRIC 76
7.4.2.3 PEDIATRIC 76
7.5 VOCLOSPORIN (ORAL CAPSULE) 76
7.6 OTHERS 77
7.6.1 GENERIC 77
7.6.2 BRANDED 77
8 MIDDLE EAST AND AFRICA CALCINEURIN INHIBITORSMARKET, BY DRUG TYPE 78
8.1 OVERVIEW 79
8.2 GENERIC 82
8.2.1 POSTOPERATIVE IMMUNOSUPPRESSION 82
8.2.2 ATOPIC DERMATITIS 82
8.2.3 ULCERATIVE COLITIS 82
8.2.4 PSORIASIS 83
8.2.5 KERATOCONJUNCTIVITIS 83
8.2.6 OTHERS 83
8.3 BRANDED 83
8.3.1 POSTOPERATIVE IMMUNOSUPPRESSION 84
8.3.2 ATOPIC DERMATITIS 84
8.3.3 ULCERATIVE COLITIS 84
8.3.4 PSORIASIS 84
8.3.5 KERATOCONJUNCTIVITIS 84
8.3.6 OTHERS 84
9 MIDDLE EAST AND AFRICA CALCINEURIN INHIBITORS MARKET, BY APPLICATION 85
9.1 OVERVIEW 86
9.2 POSTOPERATIVE IMMUNOSUPPRESSION 89
9.3 ATOPIC DERMATITIS 89
9.4 ULCERATIVE COLITIS 90
9.5 PSORIASIS 90
9.6 KERATOCONJUNCTIVITIS 91
9.7 OTHERS 91
10 MIDDLE EAST AND AFRICA CALCINEURIN INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION 92
10.1 OVERVIEW 93
10.2 ORAL 96
10.2.1 CAPSULE 96
10.2.2 TABLET 96
10.2.3 SOLUTION 96
10.3 TOPICAL 97
10.4 PARENTERAL 97
10.5 OTHERS 98
11 MIDDLE EAST AND AFRICA CALCINEURIN INHIBITORS MARKET, BY END USER 99
11.1 OVERVIEW 100
11.2 HOSPITALS 103
11.3 SPECIALTY CLINICS 104
11.4 HOME HEALTHCARE 104
11.5 ACADEMIC AND RESEARCH INSTITUTES 105
11.6 OTHERS 105
12 MIDDLE EAST AND AFRICA CALCINEURIN INHIBITORSMARKET, BY DISTRIBUTION CHANNEL 106
12.1 OVERVIEW 107
12.2 HOSPITAL PHARMACY 110
12.3 RETAIL PHARMACY 110
12.4 ONLINE PHARMACY 111
12.5 others 111
13 MIDDLE EAST AND AFRICA CALCINEURIN INHIBITOR MARKET, BY REGION 112
13.1 MIDDLE EAST AND AFRICA 114
14 MIDDLE EAST AND AFRICA CALCINEURIN INHIBITORS MARKET, COMPANY LANDSCAPE 173
14.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA
15 SWOT ANALYSIS 174
16 COMPANY PROFILES 175
16.1 ASTELLAS PHARMA US, INC. 175
16.1.1 COMPANY SNAPSHOT 175
16.1.2 REVENUE ANALYSIS 176
16.1.3 COMPANY SHARE ANALYSIS 176
16.1.4 PRODUCT PORTFOLIO 177
16.1.5 RECENT DEVELOPMENT 177
16.2 CHUNGHWA CHEMICAL SYNTHESIS & BIOTECH CO., LTD 178
16.2.1 COMPANY SNAPSHOT 178
16.2.2 REVENUE ANALYSIS 178
16.2.3 COMPANY SHARE ANALYSIS 179
16.2.4 PRODUCT PORTFOLIO 179
16.2.5 RECENT DEVELOPMENT 179
16.3 LUPIN 180
16.3.1 COMPANY SNAPSHOT 180
16.3.2 REVENUE ANALYSIS 180
16.3.3 COMPANY SHARE ANALYSIS 181
16.3.4 PRODUCT PORTFOLIO 181
16.3.5 RECENT DEVELOPMENT 181
16.4 HUADONG MEDICINE CO.,LTD 182
16.4.1 COMPANY SNAPSHOT 182
16.4.2 REVENUE ANALYSIS 182
16.4.3 COMPANY SHARE ANALYSIS 183
16.4.4 PRODUCT PORTFOLIO 183
16.4.5 RECENT DEVELOPMENT 183
16.5 VIATRIS INC. 184
16.5.1 COMPANY SNAPSHOT 184
16.5.2 REVENUE ANALYSIS 184
16.5.3 COMPANY SHARE ANALYSIS 185
16.5.4 PRODUCT PORTFOLIO 185
16.5.5 RECENT DEVELOPMENT 185
16.6 APOTEX INC. 186
16.6.1 COMPANY SNAPSHOT 186
16.6.2 PRODUCT PORTFOLIO 186
16.6.3 RECENT DEVELOPMENT 186
16.7 ABBVIE INC 187
16.7.1 COMPANY SNAPSHOT 187
16.7.2 REVENUE ANALYSIS 187
16.7.3 PRODUCT PORTFOLIO 188
16.7.4 RECENT DEVELOPMENT 188
16.8 ACCORD HEALTHCARE US. 189
16.8.1 COMPANY SNAPSHOT 189
16.8.2 PRODUCT PORTFOLIO 189
16.8.3 RECENT DEVELOPMENT 189
16.9 ACTIZAPHARMA 190
16.9.1 COMPANY SNAPSHOT 190
16.9.2 PRODUCT PORTFOLIO 190
16.9.3 RECENT DEVELOPMENT 191
16.10 ADVACARE PHARMA 192
16.10.1 COMPANY SNAPSHOT 192
16.10.2 PRODUCT PORTFOLIO 192
16.10.3 RECENT DEVELOPMENT 192
16.11 BIOCON 193
16.11.1 COMPANY SNAPSHOT 193
16.11.2 REVENUE ANALYSIS 193
16.11.3 PRODUCT PORTFOLIO 194
16.11.4 RECENT DEVELOPMENT 194
16.12 BAUSCH HEALTH COMPANIES INC. 195
16.12.1 COMPANY SNAPSHOT 195
16.12.2 REVENUE ANALYSIS 195
16.12.3 PRODUCT PORTFOLIO 196
16.12.4 RECENT DEVELOPMENT 196
16.13 CONCORD BIOTECH 197
16.13.1 COMPANY SNAPSHOT 197
16.13.2 REVENUE ANALYSIS 197
16.13.3 PRODUCT PORTFOLIO 198
16.13.4 RECENT DEVELOPMENT 198
16.14 DR. REDDY’S LABORATORIES 199
16.14.1 COMPANY SNAPSHOT 199
16.14.2 REVENUE ANALYSIS 199
16.14.3 PRODUCT PORTFOLIO 200
16.14.4 RECENT DEVELOPMENT 200
16.15 GLENMARK PHARMACEUTICALS INC 201
16.15.1 COMPANY SNAPSHOT 201
16.15.2 REVENUE ANALYSIS 201
16.15.3 PRODUCT PORTFOLIO 202
16.15.4 RECENT DEVELOPMENT 202
16.16 LEO PHARMA INC. 203
16.16.1 COMPANY SNAPSHOT 203
16.16.2 PRODUCT PORTFOLIO 203
16.16.3 RECENT DEVELOPMENT 203
16.17 LIPELLA PHARMACEUTICALS, INC. 204
16.17.1 COMPANY SNAPSHOT 204
16.17.2 REVENUE ANALYSIS 204
16.17.3 PRODUCT PORTFOLIO 205
16.17.4 RECENT DEVELOPMENT 205
16.18 NOVARTIS AG 206
16.18.1 COMPANY SNAPSHOT 206
16.18.2 REVENUE ANALYSIS 206
16.18.3 PRODUCT PORTFOLIO 207
16.18.4 RECENT DEVELOPMENT 207
16.19 NOVALIQ GMBH 208
16.19.1 COMPANY SNAPSHOT 208
16.19.2 PRODUCT PORTFOLIO 208
16.19.3 RECENT DEVELOPMENT 208
16.20 PANACEA BIOTEC 209
16.20.1 COMPANY SNAPSHOT 209
16.20.2 REVENUE ANALYSIS 209
16.20.3 PRODUCT PORTFOLIO 210
16.20.4 RECENT DEVELOPMENT 212
16.21 PADAGIS 213
16.21.1 COMPANY SNAPSHOT 213
16.21.2 PRODUCT PORTFOLIO 213
16.21.3 RECENT DEVELOPMENT 213
16.22 RPG LIFE SCIENCES LIMITED 214
16.22.1 COMPANY SNAPSHOT 214
16.22.2 REVENUE ANALYSIS 214
16.22.3 PRODUCT PORTFOLIO 215
16.22.4 RECENT DEVELOPMENT 215
16.23 VELOXIS PHARMACEUTICALS, INC. 216
16.23.1 COMPANY SNAPSHOT 216
16.23.2 REVENUE ANALYSIS 216
16.23.3 PRODUCT PORTFOLIO 216
16.23.4 RECENT DEVELOPMENT 216
16.24 ZHAOKE OPHTHALMOLOGY LIMITED 217
16.24.1 COMPANY SNAPSHOT 217
16.24.2 REVENUE ANALYSIS 217
16.24.3 PRODUCT PORTFOLIO 218
16.24.4 RECENT DEVELOPMENT 218
16.25 ZAMBON COMPANY S.P.A. 219
16.25.1 COMPANY SNAPSHOT 219
16.25.2 PRODUCT PORTFOLIO 219
16.25.3 RECENT DEVELOPMENT 220
17 QUESTIONNAIRE 221
18 RELATED REPORTS 224